BridgeMD
New treatment option for Post Operative Analgesia
Official title Dexmedetomidine and Bupivacaine Intra-articular for Postoperative Analgesia After Knee Arthroscopic Surgery
ClinicalTrials.gov ID: NCT06665438
What this study is testing
What is Bupivacaine 0.25%?
Bupivacaine 0.25% is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for post operative analgesia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study to compare the analgesic effects of intraarticular dexmedetomidine added to bupivacaine with those of bupivacaine alone after knee arthroscopy
- Phase 3: a large, late-stage study
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- ASA I-II patients
- Either sex
- Aged 18-65 years
- Candidates for anterior cruciate ligament (ACL) reconstruction by knee arthroscopy
You likely can't join if
- the patients with kidney failure, liver failure, valvular and ischemic heart disease , high blood pressure, diabetes, history of infection and...
- history of coagulation diseases, and history of drug allergies to used drugs.
- those who consumed NSAIDs and analgesics 24 h before surgery were excluded from the study.
The study team makes the final eligibility decision.
Where it's taking place
- Asyut, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Asyut, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.